Document is current
Any future updates will be listed below
-
Authors
Liu, Yaxin
Wang, Wei
Yin, Rutie
Zhang, Youzhong
Zhang, Yu
Zhang, Keqiang
Pan, Hongming
Wang, Ke
Lou, Ge
Li, Guiling
Zhang, Ruyan
Li, Kun
Rao, Jing
Zhang, Ben
Wang, Yuting
Wang, Quanren
Gao, Yunong
Li, Huiping
-
Funding
Funding for this research was provided by:
Jiangsu Hengrui Pharmaceuticals Co., Ltd
- License Information
-
More Information
Article History
Received: 11 March 2023
Accepted: 23 August 2023
First Online: 29 September 2023
Declarations
:
: The trial protocol was approved by the institutional review board or ethnic review committee of all participating centers: Peking University Cancer Hospital and Institute (2017YW02; 2017YW03); West China Second University Hospital, Sichuan University (Y2018009); Qilu Hospital of Shangdong University (2018007); Xiangya Hospital, Central South University (201710116); Hunan Cancer Hospital (2018 [No.193]); Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (20180206–2); Tianjin Medical University Cancer Institute and Hospital (E2018053); Harbin Medical University Cancer Hospital (2018–129); Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2018 [No.19]). All procedures were conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent before enrollment.
: Not applicable.
: JR, BZ, YW and QW were employees of Jiangsu Hengrui Pharmaceuticals at the time of study. All other authors have no conflicts of interest to declare.
